-
Product Insights
NewNet Present Value Model: Gamida Cell Ltd’s NiCord
Empower your strategies with our Net Present Value Model: Gamida Cell Ltd's NiCord report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemafibrate in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemafibrate in Hypercholesterolemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemafibrate in Hypercholesterolemia Drug Details: Pemafibrate (Parmodia) acts as dyslipidemic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-151 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Pancreatic Ductal Adenocarcinoma Drug Details: AMT-151 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Natural Killer Cell Lymphomas Drug Details: Cemiplimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PBF-999 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PBF-999 in Solid Tumor Drug Details: PBF-999 is under development for treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadravaleucel in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadravaleucel in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadravaleucel in Relapsed Multiple Myeloma Drug Details: GDA-201 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nadravaleucel in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nadravaleucel in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nadravaleucel in Refractory Multiple Myeloma Drug Details: GDA-201 is under development...
-
Product Insights
Hemoglobinopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinopathies - Drugs In Development, 2023’, provides an overview of the Hemoglobinopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Aplastic Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Aplastic Anemia - Drugs In Development, 2023’, provides an overview of the Aplastic Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hematopoietic Stem Cell Transplantation – Drugs In Development, 2023
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Drugs In Development, 2023’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...